Resona Asset Management Co. Ltd. Acquires 673,149 Shares of Biogen Inc. $BIIB

Biogen logo with Healthcare background
Image from MarketBeat Media, LLC.

Resona Asset Management Co. Ltd. lifted its stake in Biogen Inc. (NASDAQ:BIIB - Free Report) by 1,540.4% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 716,848 shares of the biotechnology company's stock after purchasing an additional 673,149 shares during the quarter. Biogen accounts for 0.8% of Resona Asset Management Co. Ltd.'s portfolio, making the stock its 19th largest position. Resona Asset Management Co. Ltd. owned about 0.48% of Biogen worth $161,922,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in BIIB. Bell Investment Advisors Inc acquired a new position in Biogen during the second quarter valued at approximately $27,000. Align Financial LLC raised its position in shares of Biogen by 339.3% in the third quarter. Align Financial LLC now owns 123 shares of the biotechnology company's stock valued at $28,000 after purchasing an additional 95 shares during the period. Provenance Wealth Advisors LLC bought a new position in shares of Biogen in the third quarter valued at approximately $29,000. Canton Hathaway LLC acquired a new stake in shares of Biogen in the third quarter worth $31,000. Finally, Financial Freedom LLC acquired a new stake in shares of Biogen in the third quarter worth $34,000. 87.93% of the stock is owned by hedge funds and other institutional investors.

Biogen Stock Up 1.0%

Shares of NASDAQ BIIB opened at $249.59 on Friday. The stock has a market cap of $36.89 billion, a PE ratio of 106.66, a PEG ratio of 2.85 and a beta of 0.10. Biogen Inc. has a 52-week low of $160.36 and a 52-week high of $261.00. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.37 and a current ratio of 1.95. The business has a fifty day moving average of $236.83 and a two-hundred day moving average of $206.86.

Biogen (NASDAQ:BIIB - Get Free Report) last issued its quarterly earnings data on Wednesday, October 28th. The biotechnology company reported $2.62 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.63. Biogen had a net margin of 3.37% and a return on equity of 9.38%. The firm had revenue of $2.80 billion for the quarter, compared to analysts' expectations of $2.63 billion. During the same period in the prior year, the firm earned $4.81 earnings per share. The company's quarterly revenue was up 10.6% compared to the same quarter last year. As a group, equities research analysts expect that Biogen Inc. will post 12.46 earnings per share for the current fiscal year.

Key Headlines Impacting Biogen

Here are a few of the latest headlines about BIIB:

  • Positive Sentiment: Biogen and Eisai reported that lecanemab slowed clinical decline over 18 months in an analysis of early Alzheimer’s patients with α-synuclein co-pathology. The subgroup results were exploratory and post hoc, but add supportive evidence for LEQEMBI’s potential reach. Article
  • Positive Sentiment: Coverage also highlighted three-year real-world LEQEMBI data reporting slower Alzheimer’s progression, another potential support for the drug’s commercial prospects. Article
  • Positive Sentiment: A new research collaboration with TRIMTECH will explore protein-degrader approaches for neurodegenerative diseases, offering possible longer-term pipeline potential, though it remains early-stage research. Article

Wall Street Analyst Weigh In

BIIB has been the subject of a number of recent analyst reports. Stifel Nicolaus set a $242.00 price target on shares of Biogen in a report on Thursday, September 10th. Wolfe Research raised Biogen from a "peer perform" rating to an "outperform" rating and set a $300.00 price objective for the company in a research report on Thursday, August 13th. Weiss Ratings downgraded Biogen from a "hold (c)" rating to a "hold (c-)" rating in a research note on Thursday, October 29th. HSBC raised their target price on Biogen from $165.00 to $175.00 and gave the company a "reduce" rating in a report on Thursday, September 10th. Finally, Piper Sandler reaffirmed an "overweight" rating and issued a $305.00 price target (up from $245.00) on shares of Biogen in a research report on Monday, November 9th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $255.45.

Get Our Latest Research Report on BIIB

Biogen Profile

(Free Report)

Biogen is a biotechnology company focused on developing and commercializing medicines for neurological and rare diseases. Its areas of focus include multiple sclerosis, Alzheimer's disease, spinal muscular atrophy and Friedreich's ataxia. Its products include multiple sclerosis treatments such as Tysabri, Tecfidera and Vumerity, and Skyclarys for Friedreich's ataxia. Biogen shares rights to several medicines with other companies, including Leqembi for Alzheimer's disease with Eisai and Spinraza for spinal muscular atrophy with Ionis Pharmaceuticals.

See Also

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Biogen Right Now?

Before you consider Biogen, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biogen wasn't on the list.

While Biogen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines